IL-7 Protein (AA 26-177)

Catalog No. ABIN2667542

Product Details

Target: IL-7 (IL7) (Interleukin 7 (IL7))

Protein Type: Recombinant

Biological Activity: Active

Protein Characteristics: AA 26-177

Origin: Human

Source: Escherichia coli (E. coli)

Application: Western Blotting (WB), Flow Cytometry (FACS), Immunoprecipitation (IP)

Purity: >98 % , as determined by Coomassie stained SDS-PAGE and HPLC analysis.

Endotoxin Level:

Less than 0.1 ng per μg of protein.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: ED50 is ≤ 0.5 ng/ml, corresponding to a specific activity of ≥ 2.0 x 106 units/mg as determined by the dose-dependent stimulation of the proliferation of mouse 2E8 cells.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: For maximum results, quick spin vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/mL. Do not vortex. It is recommended to further dilute in a buffer, such as 5 % Trehalose, and store working aliquots at -20 °C to -80 °C.

Buffer: Lyophilized, carrier-free.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored at -20°C or -70°C.

Target Details

Target: IL-7 (IL7) (Interleukin 7 (IL7))

Alternative Name: IL-7 (IL7 Products)

Synonyms: IL7 Protein, IL-7 Protein, A630026I06Rik Protein, Il-7 Protein, hlb368 Protein, interleukin 7 Protein, IL7 Protein, Il7 Protein

Background: IL-7 was initially described as a stromal derived factor which is capable of inducing the growth of pre-B cells in vitro. IL-7 acts on a variety of cells through its receptor (IL-7R), a heterodimer consisting of IL-7Rα (CD127) and a common γc chain (CD132) shared by other cytokine (IL-2, IL-4, IL-9, IL-15, and IL-21) receptors. In addition, IL-7Rα is shared with TSLP. The generation of IL-7-deficient and IL-7Rα-deficient mice and monoclonal antibody blocking experiments confirmed the requirement of IL-7 for B-cell development in mice. Nevertheless, mutations in the α chain of the IL-7 receptor in patients with severe combined immunodeficiency (SCID) confirmed that IL-7 is indispensable for T-cell development in humans. However, the presence of B cells in these individuals suggests important differences between the role of IL-7 in murine and human lymphocyte development. Thus, although human B-cell development does not appear to require IL-7, immature human B cells do proliferate in response to IL-7. Nevertheless, most recent information suggests that IL-7 dependence in human lymphopoiesis increases during the progression of ontogeny in cord blood and bone marrow. IL-7 can be associated to hepatocyte grow factor (HGFβ) to form a hybrid cytokine (IL-7/HGFβ), which induces greater proliferation of CFU-S, SLPs, and pre-pro-B cells than does native IL-7. The hybrid cytokine signals through both IL-7R (IL-7Rα plus γc) and c-Met. IL-7 has a thymic antiapoptotic effect and induces the expression of antiapoptotic proteins Bcl-2 and Mcl-1 and the inhibition of proapoptotic proteins Bax and Bad. In addition, IL-7 is a key regulator of glucose uptake in T cells. TGF-β has been shown to down-regulate IL-7 mRNA and protein secretion from human bone marrow stromal cells. In addition, TGF-β inhibits IL-7-induced proliferation of pre-B cells.

Molecular Weight: The 153 amino acid N-terminal methionylated recombinant protein has a predicted molecular mass of 17.4 kDa. The predicted N-terminal amino acid is Met.

Pathways: JAK-STAT Signaling